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Abstract
Surgery is the mainstay of treatment of rectal cancer. One 
third of all treatment failures are secondary to local recurrence 
usually leading to a painful and distressing death. Radiotherapy 
has been shown to decrease local recurrence rates and overall 
survival. The results of a local retrospective study are discussed, 
identifying and describing the recurrence rates in rectal cancer. 
Our management pathways are also reviewed and compared to 
current evidence-based medicine and published clinical trials. 
Introduction
The management of rectal cancer has undergone marked 
changes in the last twenty years leading to improved results in 
local and distant recurrence rates and overall survival.  These 
changes have occurred in the staging, surgical management, 
histological evaluation, radiotherapy and chemotherapy of the 
condition. We have carried out an audit of patients with Duke’s 
B and C rectal cancer referred to the Oncology Department in the 
years 2001 to 2003 to evaluate local and distant recurrence rates 
and to examine ways in which we can improve our results.
Methodology
One hundred and five patients with rectal cancer were 
referred to the oncology department between the years 2001 to 
2003 inclusive. Of these 68 patients were Duke’s stage B and 
Duke’s stage C the remainder being either Duke’s stage A or 
Duke’s stage D. These were the only patients eligible for adjuvant 
treatment, since this is not indicated in the management of 
Duke’s A or Duke’s D. 
Of those 68 patients, 35 were Duke’s Stage B and 33 Stage C. 
Records have been traced on 57 patients out of 68 patients, 30 
with Duke’s B and 27 with Duke’s C. These 57 patients constitute 
the population for this audit, which is aimed at trying to improve 
our results by changing our practice.
The records of 11 of these 68 patients could not be traced 
and therefore they were not included in the study. The histology 
report of 9 of these patients was traced and 3 are known to have 
been Duke’s stage B and 6 are known to have been stage Duke’s 
stage C. Also, of these eleven patients staged B and C, where 
records were not traced, 7 are known to be dead. However, the 
cause of death obtained from tracing records of the patients’ 
death certificate does not specify if these patients developed a 
recurrence of the disease or not. Also, the accuracy of such data 
is questionable. The lack of complete records almost certainly 
introduces bias to our findings. This means that our results for 
the whole group are likely to be worse than in the 57 patients 
whose records are complete.  Nonetheless the study remains a 
useful exercise in the ultimate aim of improving our practice.
Results
Twenty three per cent of Duke’s B and 7.4% of Duke’s C 
patients suffered a local recurrence by the time of the audit (June 
2007) and 20% of Duke’s B and 14.8% of Duke’s C suffered a 
distant recurrence at the time of first relapse. One patient with 
Duke’s C (3.7%) suffered both a local and distant recurrence. 
The overall recurrence rate for Duke’s B was 43% and for Duke’s 
C 25.9% (figure 1).  
Figure 2 gives a breakdown of treatment received by all 
Duke’s B and C patients referred. Seventy six per cent of Duke’s 
B patients received radiotherapy only, 4% chemotherapy only 
and 16% both chemotherapy and radiotherapy. Four per cent 
of Duke’s B patients received no further treatment. Sixty-
eight per cent of patients with Duke’s C rectal cancer received 
radiotherapy and chemotherapy, 29 % received radiotherapy 
alone and 3% chemotherapy only.  
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Figures 3 and 4 illustrate the type of post-operative 
treatment received by patients, who eventually developed a 
recurrence. The majority of Duke’s B patients received post-
operative radiotherapy, with only one having received pre-
operative radiotherapy. 
All patients underwent complete resection of the tumour 
either a low anterior resection or an abdominoperineal resection. 
Chemotherapy consisted of weekly 5-Fluorouracil and folinic 
acid.
Discussion
The management of rectal cancer, once this has been 
diagnosed, starts with adequate staging to determine the optimal 
treatment for each individual patient. The use of endorectal 
ultrasound, CT Scanning and MRI Scanning allows much more 
accurate determination of T stage, nodal involvement and 
distant metastasis (TNM).
Endorectal ultrasound provides the most accurate method of 
assessing depth of bowel wall invasion for early tumours i.e. T1 
and T2 tumours but is less useful for tumours extending beyond 
this.1 It is also operator dependent to a greater extent than CT 
and MRI.  To assess the risk of involvement of the mesorectal 
excision plane and therefore the risk of local recurrence MRI is 
the preferred modality of imaging especially MRI with a phased 
array coil.2
CT Scanning is still the modality of choice for assessing 
distant spread and modern multi-slice CT would allow distant 
and local staging in a single investigation. A 4–16 slice CT is 
satisfactory for high rectal tumours with a wide circumferential 
resection margin, which are at low risk of recurrence but 
inadequate for low rectal tumours especially in less experienced 
hands. The newer 64–128 slice CT Scans may well alter this 
scenario.3
For the assessment of nodal involvement, CT is generally 
unsatisfactory. Endorectal Ultrasound is very useful especially 
for guiding fine needle aspiration but the latter technique 
though highly accurate is not widely used. MR with new contrast 
agents is the investigation of choice for assessing pelvic node 
involvement. FDG – PET has so far been disappointing in 
detecting the low volume nodal disease usually seen in rectal 
cancer.
It is now clearly established that the type of operation 
carried out (quality of the surgery) has a major impact on local 
recurrence rates and ultimately survival.4  The introduction 
of total mesorectal excision (TME) has been accompanied by 
a marked reduction in local recurrence rates. This procedure 
involves a longer operation with an increased complication 
rate but produces a local recurrence rate in “curative” surgery 
of around 4% at 5 years and overall recurrence rate of around 
18%.5,6 The best reported results from the North Central Cancer 
Treatment Group for resectable tumours with conventional 
surgery (i.e. non TME) plus radiotherapy or combined chemo 
radiation for local recurrence are 25% and 13.5% respectively at 
5 years and 62.7% and 41.5% for overall recurrence.
The results from TME have been replicated in a number 
of centres and indicate that the poorer results of conventional 
surgery cannot be compensated for by radiation or chemo 
radiation.  For tumour in the middle or distal rectum TME is 
always indicated.
The pathologist too has an important role to play in 
improving results in the management of rectal cancer. The 
pathologist’s report serves as an important audit of surgical 
technique and guides the selection of patients for post-operative 
adjuvant treatment. The radiologist’s report should guide the 
selection of patients for pre-operative treatment.
For many years it has been standard local practice to operate 
patients with rectal cancer and refer them post-operatively to the 
oncology department. This has the advantage of allowing more 
accurate staging, an advantage that should be largely eliminated 
by using optimal staging imaging pre-operatively. It has the 
disadvantage of denying patients pre-operative radiotherapy 
or chemo radiation.
There is now a consensus based on several clinical trials 
that pre-operative radiotherapy decreases the local recurrence 
rate even if the operative procedure is a TME.7 A meta-analysis 
of 14 randomised controlled trials showed that pre-operative 
radiotherapy significantly improves survival and 5 year cancer 
specific survival with marked reductions in local recurrence 
rates.8 It is also clearly established that pre-operative 
Figure 1: Percentage of Recurrence in patients with 
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Figure 2: Treatment of patients with Duke’s B 
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radiotherapy offers superior results when compared to post-
operative radiation as well as decreased toxicity.  No trial of 
post-operative radiation has shown a survival advantage.
If the circumferential resection margin is not threatened 
and the tumour is not too distal, a short 5 day course of pelvic 
radiation followed one week later by surgery is effective in 
reducing local recurrence.
Two studies comparing pre-operative radiation versus pre-
operative radiation plus 5-Fluorouracil/leucovorin pre-operative 
chemotherapy, showed a reduction in local recurrence rate for the 
chemo radiation arm without an improvement in overall survival. 
It is hoped that the use of chemotherapy regimens known to 
have higher response rates in the metastatic setting (FOLFOX/
FOLFIRI) as well as improved survival in the adjuvant setting may 
impact on overall survival. The use of new biological therapies, 
such as Bevacizumab, offers similar hope.
In our series only one patient was referred pre-operatively 
between 2001 and 2003. Happily this practice is beginning to 
change with several patients with fixed inoperable tumours 
referred over the last few years and more recently patients 
with more advanced but operable tumours. For those with 
bulkier/fixed tumours we are using combined pelvic radiation 
and FOLFOX (5-Fluorouracil, leucovorin and Oxaliplatin). 
The protocol has considerable toxicity and is unsuitable for 
frail patients but is certainly manageable in fitter patients and 
is beginning to produce gratifying results at least in terms to 
tumour response. It is still too early to comment about local 
recurrence and overall recurrence rates. This will be the subject 
of a future audit.
Local recurrence of a rectal cancer is painful, causes marked 
morbidity and deterioration of quality of life.  Treatment that 
can be offered is usually palliative and such a relapse therefore 
ultimately leads to death of the patient.
Our local recurrence rates for the years 2001 – 2003 (16% 
Duke’s B and C) are disappointingly high compared to what 
can be achieved by TME alone (4% localized recurrence). The 
Swedish Rectal Cancer Trial reported 25% local recurrence 
rates with conventional surgery, reduced to 11% by short course 
pre-operative radiotherapy.9 A Dutch Rectal Study comparing 
TME versus short course pre-operative RT and TME showed 
reduction in local recurrence rate from 8.2% for surgery alone 
to 2.4% for combined treatment. In our series 92% of Duke’s B 
patients received radiotherapy, 16% receiving both chemotherapy 
and radiotherapy. Twenty three per cent of these suffered a local 
relapse.  Radiotherapy in all but one patient was however delivered 
solely post-operatively and this is known to be less effective. The 
lower local relapse rate in the Duke’s C group (7.4%) is counter 
intuitive and the distant recurrence rate (14.8%) even more so. It 
may reflect the higher use of chemotherapy (72%) in this group 
but numbers are too small to draw a conclusion. Also one should 
consider the possibility of understaging due to harvesting and 
examination of an inadequate number of nodes for our Duke’s B 
series. TNM and NICE guidelines suggest a minimum of 12 nodes 
should be harvested.10 The impact of adjuvant chemotherapy on 
Duke’s B cancer is minimal – of the order of 1–2 % reduction 
in overall recurrence at 5 years with 5-Fluorouracil based 
chemotherapy and marginally better with FOLFOX. Twenty 
per cent of our Duke’s B patients received chemotherapy. This 
seems difficult to justify but must be seen in the light of unreliable 
staging, younger patients who would be treated more aggressively 
and poorly differentiated tumour. The evidence for benefit in B2 
tumour is controversial. Not withstanding these figures require 
a review of our policies.
With Duke’s C rectal cancer the impact of adjuvant 
chemotherapy is larger – around 12% absolute difference in 
survival at 5 years with 5-Fluorouracil based chemotherapy and 
15% with FOLFOX for patients with 1–3 involved nodes. Again 
the difference in outcome between the two regimes barely justifies 
the increased toxicity and cost of FOLFOX. The benefit from 
chemotherapy increases the worse the prognosis, so that FOLFOX 
becomes justified in younger fitter patients with more than 10 
nodes involved and poorly differentiated tumour (18% alive due 
to 5-Fluorouracil based chemotherapy versus 25% for FOLFOX 
at 5 years). Oxaliplatin is not available for use in the adjuvant 
setting in Malta’s public hospitals but is widely used in metastatic 
disease. The new drugs oxaliplatin and irinotecan were not used 
at all in adjuvant treatment in the period under review.
Our figures for overall recurrence (43% Duke’s B and 27.4% 
Duke’s C) are difficult to explain but statistics in small numbers 
can be misleading. However, they do not compare well with the 
Figure 3: Post-operative treatment in Duke’s B who later 
developed a recurrence
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Figure 4: Post-operative treatment in Duke’s C who later 
developed a recurrence
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figures of Duke’s B and C combined, treated with TME alone7 
(18% overall recurrence). They approach more those treated 
by conventional surgery and radiation (63% for Duke’s B and 
C combined) or conventional surgery and chemo radiation 
(41.5%). Even if the groups are not strictly comparable and 
our numbers are small the implication is clear, that TME has a 
major impact both on local and overall recurrence, pre-operative 
radiotherapy further reduces local recurrence, and that adjuvant 
chemotherapy reduces overall recurrence rate, at least in Duke’s 
C rectal cancer.
Conclusion
As the title indicates the audit was aimed at a review of 
recurrence rates of rectal cancer patients and more specifically 
to look at the way these patients are investigated and treated in 
order to come up with a protocol that will improve results.
Disease free survival (DFS) is therefore very much a point 
examined by the audit though overall survival (OS) was not since 
most distant and local recurrences are ultimately fatal.
The above data urgently call for the implementation of 
new protocols using appropriate imaging, referral of selected 
patients for pre-operative radiation or chemo radiation and 
finally adequate surgery, audited by a detailed and accurate 
pathology report.
A proposed plan of action for optimal diagnosis and 
management of rectal tumours is as follows:
1. Endoscopy and biopsy
2. Pelvic MRI
3. CT thorax, abdomen and pelvis to exclude distant metastasis.
4. Referral for pre-operative radiotherapy if circumferential 
resection margin is threatened or for fixed or bulky tumours.
5. TME is carried our for all patients with middle or low rectal 
tumours
6. Pathology report is to audit the adequacy of surgical 
technique and indicate best post-operative treatment 
 e.g. +/- chemotherapy.
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